The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2019
Filed:
Feb. 28, 2019
Applicant:
Puretech Health Llc, Boston, MA (US);
Inventors:
Eric Elenko, Boston, MA (US);
Philip E. Murray, III, Somerville, MA (US);
Andrew C. Miller, East Walpole, MA (US);
Assignee:
PureTech Health LLC, Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/46 (2006.01); A61K 9/48 (2006.01); A61K 31/4439 (2006.01); A61K 31/222 (2006.01); A61K 31/4025 (2006.01); A61K 31/4178 (2006.01); A61K 31/438 (2006.01); A61K 31/44 (2006.01); A61K 31/4725 (2006.01); A61K 45/06 (2006.01); A61K 31/138 (2006.01);
U.S. Cl.
CPC ...
A61K 31/46 (2013.01); A61K 9/48 (2013.01); A61K 9/485 (2013.01); A61K 9/4825 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 9/4891 (2013.01); A61K 31/138 (2013.01); A61K 31/222 (2013.01); A61K 31/4025 (2013.01); A61K 31/4178 (2013.01); A61K 31/438 (2013.01); A61K 31/44 (2013.01); A61K 31/4439 (2013.01); A61K 31/4725 (2013.01); A61K 45/06 (2013.01);
Abstract
The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.